Dresser George K, Bailey David G
Department of Medicine, University of Western Ontario, Lawson Health Research Institute, London, Canada.
Can J Clin Pharmacol. 2002 Winter;9(4):191-8.
Drug interactions are frequently the result of altered activity of the mechanism(s) responsible for drug elimination. These include drug metabolism mediated by a select group of cytochrome P450 enzymes (CYP3A4, CYP2D6, CYP2C9, CYP2C19, CYP1A2) and drug transporters (P-glycoprotein). Adverse drug interactions can result from induction (loss of therapeutic benefit) or inhibition (increased toxicity from excessive effect) of drug elimination. CYPs and P-glycoprotein are discussed individually with regards to their characteristics, frequently prescribed drug substrates, inducers and inhibitors, and important adverse drug events. The potential for important drug interactions can be predicted based on the properties of the causative agent (oral bioavailability, mechanism of elimination, seriousness of adverse event) and the interacting agent. Consequently, drug interactions can be prevented by avoiding concomitant administration of interacting substances or possibly implementing alternative therapeutic strategies. Furthermore, susceptibility to adverse events depends not only on the interacting substances, but also on the patient and the method of drug administration. Commonly prescribed drugs that are unlikely to cause a drug interaction involving CYPs or P-glycoprotein are also discussed.
药物相互作用通常是负责药物消除的机制活性改变的结果。这些机制包括由一组特定的细胞色素P450酶(CYP3A4、CYP2D6、CYP2C9、CYP2C19、CYP1A2)介导的药物代谢以及药物转运体(P-糖蛋白)。不良药物相互作用可能源于药物消除的诱导(治疗益处丧失)或抑制(因作用过度导致毒性增加)。将分别讨论细胞色素P450酶和P-糖蛋白的特性、常用的药物底物、诱导剂和抑制剂以及重要的不良药物事件。基于致病药物(口服生物利用度、消除机制、不良事件的严重程度)和相互作用药物的特性,可以预测重要药物相互作用的可能性。因此,可以通过避免同时使用相互作用的物质或可能实施替代治疗策略来预防药物相互作用。此外,对不良事件的易感性不仅取决于相互作用的物质,还取决于患者和药物给药方法。还将讨论通常不太可能引起涉及细胞色素P450酶或P-糖蛋白的药物相互作用的常用药物。